The addition of rituximab to chemotherapy in patients with CD5+ DLBCL revealed a significant improvement in PFS (47.4% vs. 62.5%) at 4 years, but not in OS (57.8% vs. 63.5%) at 4 years 40. Here, CD5 is linked to diffuse large B-cell lymphoma.